Revenue: As of FY2025 Q3, the actual value is USD 2.289 M.EPS: As of FY2025 Q3, the actual value is USD -4.33.EBIT: As of FY2025 Q3, the actual value is USD -102.71 M.<h3>Medical Device Packaging Segment</h3><ul><li>Net Revenue: $306,344 for the nine months ended September 30, 2025.</li><li>Total Cost of Goods Manufactured: $2,508,027 for the nine months ended September 30, 2025.</li><li>Gross Margin (Loss): - $2,201,683 for the nine months ended September 30, 2025.</li><li>Research and Development: $295,579 for the nine months ended September 30, 2025, a decrease from $523,347 for the same period in 2024.</li><li>Selling, General and Administrative: $114,571,809 for the nine months ended September 30, 2025, an increase from $5,257,015 for the same period in 2024.</li><li>Impairment of Long-Lived Fixed Assets: $7,497,669 for the nine months ended September 30, 2025.</li></ul><h3>Digital Assets Segment</h3><ul><li>Staking Revenue: $2,205,423 for the nine months ended September 30, 2025.</li><li>Transaction Expenses: $810,861 for the nine months ended September 30, 2025.</li><li>Realized and Unrealized Gains on Digital Assets: $15,499,742 for the nine months ended September 30, 2025.</li><li>Derivative Gain (Loss), Net: - $4,378,749 for the nine months ended September 30, 2025.</li></ul><h3>Corporate</h3><ul><li>Net Interest Income (Expense): - $461,551 for the nine months ended September 30, 2025, compared to - $46,503 for the same period in 2024.</li><li>FMV Adjustment for Warrants: $12,295,842 for the nine months ended September 30, 2025, compared to $2,088,747 for the same period in 2024.</li><li>Other Income (Expense): - $1,000,090 for the nine months ended September 30, 2024.</li><li>Foreign Currency Gain (Loss): $371,741 for the nine months ended September 30, 2025, compared to - $31,566 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue its focus on the marketing and distribution of syringe products and related drug-delivery systems, while no longer engaging in research, design, and manufacturing activities.</li><li>Non-Core Business: The company has adopted a digital asset treasury strategy focused on accumulating Solana (SOL) and has begun exploring strategic acquisitions and/or investments globally.</li><li>Share Repurchase Program: The company has approved a share repurchase program providing for the repurchase of up to $100,000,000 of its outstanding shares of Common Stock.</li></ul>

SHARPS TECHNOLOGY INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 2.289 M